Department of Genomics & Cytogenetics, Institute of Biomedicine and Pharmacy (IBP), Vietnam Military Medical University, Hanoi, Viet Nam.
Top Data Science Ltd, Helsinki, Finland.
Clin Chim Acta. 2022 Jun 1;531:309-317. doi: 10.1016/j.cca.2022.04.997. Epub 2022 Apr 29.
Asymptomatic transmission was found to be the Achilles' heel of the symptom-based screening strategy, necessitating the implementation of mass testing to efficiently contain the transmission of COVID-19 pandemic. However, the global shortage of molecular reagents and the low throughput of available realtime PCR facilities were major limiting factors.
A novel semi-nested and heptaplex (7-plex) RT-PCR assay with melting analysis for detection of SARS-CoV-2 RNA has been established for either individual testing or 96-sample pooled testing. The complex melting spectrum collected from the heptaplex RT-PCR amplicons was interpreted with the support of an artificial intelligence algorithm for the detection of SARS-CoV-2 RNA. The analytical and clinical performance of the semi-nested RT-PCR assay was evaluated using RNAs synthesized in-vitro and those isolated from nasopharyngeal samples.
The LOD of the assay for individual testing was estimated to be 7.2 copies/reaction. Clinical performance evaluation indicated a sensitivity of 100% (95% CI: 97.83-100) and a specificity of 99.87% (95% CI: 99.55-99.98). More importantly, the assay supports a breakthrough sample pooling method, which makes possible parallel screening of up to 96 samples in one real-time PCR well without loss of sensitivity. As a result, up to 8,820 individual pre-amplified samples could be screened for SARS-CoV-2 within each 96-well plate of realtime PCR using the pooled testing procedure.
The novel semi-nested RT-PCR assay provides a solution for highly multiplex (7-plex) detection of SARS-CoV-2 and enables 96-sample pooled detection for increase of testing capacity. .
无症状传播被发现是基于症状的筛查策略的致命弱点,因此需要实施大规模检测,以有效地控制 COVID-19 大流行的传播。然而,全球分子试剂短缺和现有实时 PCR 设备通量低是主要的限制因素。
建立了一种新型的半巢式和七重(7 重)实时 RT-PCR 检测方法,带有熔解分析,用于检测 SARS-CoV-2 RNA。从 7 重 RT-PCR 扩增子收集的复杂熔解光谱通过人工智能算法进行解释,用于检测 SARS-CoV-2 RNA。使用体外合成的 RNA 和鼻咽样本中分离的 RNA 评估半巢式 RT-PCR 检测方法的分析和临床性能。
该检测方法的个体检测 LOD 估计为 7.2 个拷贝/反应。临床性能评估表明,敏感性为 100%(95%CI:97.83-100),特异性为 99.87%(95%CI:99.55-99.98)。更重要的是,该检测方法支持突破性的样本混合方法,可以在一个实时 PCR 孔中同时平行筛查多达 96 个样本,而不会降低敏感性。因此,使用混合检测程序,每个实时 PCR 96 孔板可筛查多达 8820 个预扩增的 SARS-CoV-2 个体样本。
新型半巢式 RT-PCR 检测方法为 SARS-CoV-2 的高通量(7 重)检测提供了一种解决方案,并实现了 96 样本混合检测,以提高检测能力。